Barclays PLC Has $344,000 Stake in Nevro Corp. (NYSE:NVRO)

Barclays PLC reduced its stake in shares of Nevro Corp. (NYSE:NVRO) by 59.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 61,496 shares of the medical equipment provider’s stock after selling 88,518 shares during the period. Barclays PLC’s holdings in Nevro were worth $344,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its position in shares of Nevro by 7.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 127,866 shares of the medical equipment provider’s stock worth $1,077,000 after purchasing an additional 8,673 shares during the period. Rhumbline Advisers lifted its holdings in Nevro by 5.0% in the second quarter. Rhumbline Advisers now owns 58,995 shares of the medical equipment provider’s stock valued at $497,000 after buying an additional 2,836 shares during the period. Acadian Asset Management LLC boosted its position in Nevro by 154.1% during the second quarter. Acadian Asset Management LLC now owns 241,186 shares of the medical equipment provider’s stock valued at $2,029,000 after acquiring an additional 146,276 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Nevro by 5.0% during the 2nd quarter. Renaissance Technologies LLC now owns 368,100 shares of the medical equipment provider’s stock worth $3,099,000 after acquiring an additional 17,600 shares during the period. Finally, Blair William & Co. IL raised its position in shares of Nevro by 13.9% in the 2nd quarter. Blair William & Co. IL now owns 59,404 shares of the medical equipment provider’s stock worth $500,000 after acquiring an additional 7,250 shares in the last quarter. Institutional investors own 95.52% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on NVRO. Wells Fargo & Company decreased their target price on Nevro from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Robert W. Baird raised their price objective on shares of Nevro from $5.00 to $6.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 12th. JMP Securities reiterated a “market perform” rating on shares of Nevro in a research report on Tuesday, November 12th. Canaccord Genuity Group cut their target price on shares of Nevro from $7.00 to $4.00 and set a “hold” rating on the stock in a research note on Monday, December 9th. Finally, StockNews.com raised shares of Nevro from a “sell” rating to a “hold” rating in a research note on Tuesday, November 19th. Three equities research analysts have rated the stock with a sell rating and eleven have given a hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $6.30.

Nevro Price Performance

Shares of NYSE NVRO opened at $3.71 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 5.02 and a quick ratio of 3.76. The company has a 50-day moving average price of $4.42 and a 200-day moving average price of $5.93. The stock has a market capitalization of $139.02 million, a P/E ratio of -1.96 and a beta of 0.86. Nevro Corp. has a 1 year low of $3.52 and a 1 year high of $21.66.

Nevro (NYSE:NVRO) last released its quarterly earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.40. The business had revenue of $96.60 million during the quarter, compared to the consensus estimate of $93.09 million. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. The company’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.65) EPS. On average, equities research analysts forecast that Nevro Corp. will post -2.43 EPS for the current fiscal year.

Nevro Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.